search
Back to results

Pancreatic Enzymes and Bile Acids in Acutely Ill Severely Malnourished Children (PB-SAM)

Primary Purpose

SEPSIS, MALNUTRITION, CHILD

Status
Active
Phase
Phase 2
Locations
International
Study Type
Interventional
Intervention
Pancreatic Enzyme
Ursodeoxycholic acid
Pancreatic Enzyme placebo
Ursodeoxycholic acid placebo
Sponsored by
University of Oxford
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for SEPSIS focused on measuring "small intestinal bacterial overgrowth", "severe malnutrition", "factorial", "pancreatic enzymes", "bile acids", "bacterial", "translocation", "dysbiosis", "inflammation"

Eligibility Criteria

2 Months - 59 Months (Child)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Age 2 to <59 months
  • Admitted to hospital with an acute, non-traumatic illness and within 72 hours of admission at the time of enrolment
  • Severe malnutrition (weight-for-height <-3 z scores of the median WHO growth standards and/or mid upper arm circumference <115mm (<110mm age below 6 months), or symmetrical oedema of at least the feet related to malnutrition (not related to a primary cardiac or renal disorder)
  • Able to feed orally in usual state of health.
  • Accompanied by care provider who provides written informed consent
  • Primary caregiver plans to stay in the study area during the duration of the study
  • Presence of two or more features of severity as specified below. If a child meets two criteria, they may be enrolled before further criteria are assessed (e.g. a child may be eligible on clinical signs before the complete blood count results are known):

Respiratory distress "Subcostal indrawing" or "nasal flaring" or "head-nodding" Oxygenation "Central cyanosis" or SaO2 <90% Circulation Limb temperature gradient or capillary refill >3 seconds Conscious level AVPU < "A" Pulse > 180 per min Haemoglobin < 7g/dl Blood glucose < 3mmol/L White blood cells < 4 or > 17.5 x 109/L Temperature <36 or >38.5oC Very low MUAC MUAC <11cm

Exclusion Criteria:

Sites / Locations

  • ICDDR,B Dhaka Hospital
  • KEMRI WT Clinical Trials Facility
  • Queen Elizabeth Central Hospital
  • Mulago Hospital

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Active Comparator

Placebo Comparator

Active Comparator

Placebo Comparator

Arm Label

Pancreatic Enzymes (PE)

Placebo-PE

Ursodeoxycholic acid (UA)

Placebo-UA

Arm Description

Pancreatic enzymes formulated as 5000 IE lipase, 3600 IE amylase and 200 IE protease per 100 mg of granules, packaged as sachets. The target dose is 3000 IU lipase/kg, twice daily (1440 IU/kg amylase/80 IU/kg protease), which is the dose used for children with cystic fibrosis and exocrine pancreas insufficiency. For oedematous malnutrition, weight for dosing is reduced by 10%. To be prescribed following enrolment and given just prior to or during a feed. Prescription will follow weight bands to allow a lower range of 2000 IU/kg/day and upper range of 4000 IU/kg/day: Weight from Weight to Dose Dose Upper range Lower range (Kg) (Kg) (sachets) (IU Lipase) (IU/kg/dose) (IU Lipase) ---------------------------------------------------------------------------------------------------------- 2.50 4.99 2 10000 4000 2000 5.00 7.49 4 20000 4000 2670 7.50 9.99 6 30000 4000 3000 10.0 15.0 8 40000 4000 2667

Oral/enteral placebo matching active Pancreatic Enzymes (PE). Dose presentation in whole sachets of 100mg of granules. For oedematous malnutrition, weight for dosing is reduced by a pragmatic 10%. To be prescribed following enrolment and given just prior to or during a feed. Prescription will follow weight bands: Weight from Weight to Dose Dose Upper range Lower range (Kg) (Kg) (sachets) (IU Lipase) (IU/kg/dose) (IU Lipase) ----------------------------------------------------------------------------------------------------------------------------------------- 2.50 4.99 2 Nil Nil Nil 5.00 7.49 4 Nil Nil Nil 7.50 9.99 6 Nil Nil Nil 10.0 15.0 8 Nil Nil Nil

The dose of ursodeoxycholic acid will be given at 10 mg/kg twice per day just prior to or during a feed, using a suspension of 50 mg/ml = 0.2 ml/kg. For oedematous malnutrition participants, weight is pragmatically reduced by 10%. To be prescribed and given following enrolment.

The dose of placebo will be given twice per day just prior to or during a feed at 0.2 ml/kg. To be prescribed and given following enrolment.

Outcomes

Primary Outcome Measures

Mortality
Death

Secondary Outcome Measures

Rate of SAEs
All serious adverse events
Rate of toxicity events
Grade 3 or 4 toxicity events whilst receiving investigational products
Intestinal function
number of days with diarrhoea during index hospital admission
Antimicrobials
Days on second and third-line antibiotics during index admission and readmission
Hospitalisation duration
Number of days from enrolment to discharge during index admission
Growth - arm circumference cm
Change in MUAC in cm between enrolment and 60 days later
Growth - weight for age z score
Change in weight for age z score between enrolment and 60 days later
Growth - weight for length z score
Change in weight for length z score between enrolment and 60 days later
Growth - length for age z score
Change in length for age z score between enrolment and 60 days later

Full Information

First Posted
August 6, 2020
Last Updated
February 21, 2023
Sponsor
University of Oxford
Collaborators
University of Amsterdam, University of Toronto, University of Washington, Oregon Health and Science University, Kenya Medical Research Institute, Queen Elizabeth Central Hospital, Blantyre, Malawi, Makerere University, KEMRI-Wellcome Trust Collaborative Research Program, International Centre for Diarrhoeal Disease Research, Bangladesh
search

1. Study Identification

Unique Protocol Identification Number
NCT04542473
Brief Title
Pancreatic Enzymes and Bile Acids in Acutely Ill Severely Malnourished Children
Acronym
PB-SAM
Official Title
Pancreatic Enzymes and Bile Acids: A Non-Antibiotic Approach to Treat Intestinal Dysbiosis in Acutely Ill Severely Malnourished Children
Study Type
Interventional

2. Study Status

Record Verification Date
February 2023
Overall Recruitment Status
Active, not recruiting
Study Start Date
July 1, 2021 (Actual)
Primary Completion Date
October 31, 2023 (Anticipated)
Study Completion Date
June 30, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Oxford
Collaborators
University of Amsterdam, University of Toronto, University of Washington, Oregon Health and Science University, Kenya Medical Research Institute, Queen Elizabeth Central Hospital, Blantyre, Malawi, Makerere University, KEMRI-Wellcome Trust Collaborative Research Program, International Centre for Diarrhoeal Disease Research, Bangladesh

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Children with severe malnutrition who are sick and admitted to hospitals have high mortality, usually because of infection. Malnourished children have more potentially harmful bacteria in their upper intestines than well-nourished children and this may contribute to inflammation in the gut and whole body. These bacteria may cross from the intestines to the bloodstream causing life-threatening infections. A related abnormality among malnourished children is reduction in the digestive enzymes made by the pancreas and the liver. Apart from helping with digestion of food, these enzymes are important in helping the body control bacteria in the upper intestines. It is therefore possible that treatment with digestive enzymes could help reduce the burden of harmful bacteria and thus lower inflammation and the risk of serious infection. One study conducted in Malawi has shown that children with severe malnutrition who were supplemented with pancreatic enzymes had a lower risk of dying. However, this was a small study and although promising, requires validation. No studies of supplementation with bile acids have been done among severely malnourished children. However, bile acids are commonly used to manage patients with liver function abnormalities, something that malnourished children suffer from as well. The investigators want to find out if supplementing these pancreatic enzymes and bile acids among ill children with severe acute malnutrition is safe and reduces the risk of death, deterioration or readmission to hospital.
Detailed Description
Severely malnourished children who present with an acute illness have a high risk of mortality. Severe malnutrition is associated with intestinal inflammation and changes in the fecal microbiome ('dysbiosis'). Apart from in the large intestine, dysbiosis is also present in the small (upper) intestine, where increased bacterial density and altered microbial composition can contribute to intestinal inflammation and intestinal dysfunction which may ultimately contribute to the development of sepsis and death. The bacterial density and composition in the small intestine can be altered using antibiotics. However, apart from side effects, antibiotic use contributes to the development of antibiotic resistance, which is very common in hospitalized malnourished patients and can pose a threat to both individual and public health. In addition to intestinal dysbiosis and intestinal inflammation, children with severe malnutrition suffer from impaired exocrine pancreatic and hepatobiliary function, which are important for nutrient digestion and absorption to aid their recovery. One previous pilot trial showed that treating children with severe malnutrition with pancreatic enzymes led to a reduction in mortality. The investigators hypothesize that supplementing these enzymes exogenously to severely malnourished children will improve their clinical outcome by reducing dysbiosis, intestinal inflammation and sepsis. The objective of this study is to determine whether treating ill severely malnourished children with pancreatic enzymes or bile acids is safe and improves mortality. The investigators will conduct a double blind, randomized clinical trial in a 2x2 factorial design in hospitalized severely malnourished children. Participants will be treated with pediatric formulations of pancreatic enzymes, bile acids, both or placebo for 21 days. Participants will be followed up daily during their hospital stay and on day 21 and 60 after enrollment. This trial will be conducted in three stages to allow for careful interim evaluations to assess safety and study progress. After the first and second stage, interim analyses assess safety and likelihood of benefit before enrolling the full sample size to assess mortality as the primary outcome. Secondary outcomes include adverse events, length of hospital stay and growth. Exploratory outcomes will examine intestinal and systemic inflammation and metabolic changes to examine mechanisms affected by the interventions, and costs. Two sub-studies will be conducted. In Kenya and Bangladesh, daily blood gases, lactate and biochemistry for the first 5 days to assess early clinical progress. In Malawi and Uganda, hydrogen breath testing will be used to evaluate impact on upper small intestinal bacterial overgrowth. Overall, this trial will determine whether a non-antibiotic, bactericidal intervention given in additional to standard of care management reduces mortality in acutely ill severely malnourished children.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
SEPSIS, MALNUTRITION, CHILD
Keywords
"small intestinal bacterial overgrowth", "severe malnutrition", "factorial", "pancreatic enzymes", "bile acids", "bacterial", "translocation", "dysbiosis", "inflammation"

7. Study Design

Primary Purpose
Prevention
Study Phase
Phase 2, Phase 3
Interventional Study Model
Factorial Assignment
Model Description
Double-blind, randomized clinical trial 2x2 factorial design in 3 stages: In stage 1, (200 participants). Then the Data & Safety Monitoring Committee (DSMC) will review data for likelihood major safety signals/harm (non-inferior to placebo) based on a composite endpoint of toxicity, serious adverse events (SAEs) and deaths. In stage 2, (200 more participants, total 400 participants). Then the DSMC will review data on a composite endpoint of SAEs and deaths and results of modeled simulations for the likelihood of superiority over placebo for mortality. Interventions with less than 80% probability of efficacy will be discontinued. Sample size for stage 3 may be adjusted. In stage 3, (800 more participants, total target sample size 1,200) across all sites, based on a hazard ratio of 0.66 (a 33% reduction in mortality) from a baseline mortality of 24% to 16% with 90% power, 20% inflation for the factorial design and 5% loss to follow up.
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Masking Description
Sequential study numbers will be computer generated according to a blocked randomization list of random block sizes allocated to each site before the study begins. Identical study investigation medical product (IMP) packs will be labelled with sequential study numbers according to a prepared blocked randomization list before the trial begins. An independent off-site trial-pharmacist will implement labeling of the IMP with unique study numbers according to the randomization list. Study numbers will be issued in consecutive order at each site.
Allocation
Randomized
Enrollment
400 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Pancreatic Enzymes (PE)
Arm Type
Active Comparator
Arm Description
Pancreatic enzymes formulated as 5000 IE lipase, 3600 IE amylase and 200 IE protease per 100 mg of granules, packaged as sachets. The target dose is 3000 IU lipase/kg, twice daily (1440 IU/kg amylase/80 IU/kg protease), which is the dose used for children with cystic fibrosis and exocrine pancreas insufficiency. For oedematous malnutrition, weight for dosing is reduced by 10%. To be prescribed following enrolment and given just prior to or during a feed. Prescription will follow weight bands to allow a lower range of 2000 IU/kg/day and upper range of 4000 IU/kg/day: Weight from Weight to Dose Dose Upper range Lower range (Kg) (Kg) (sachets) (IU Lipase) (IU/kg/dose) (IU Lipase) ---------------------------------------------------------------------------------------------------------- 2.50 4.99 2 10000 4000 2000 5.00 7.49 4 20000 4000 2670 7.50 9.99 6 30000 4000 3000 10.0 15.0 8 40000 4000 2667
Arm Title
Placebo-PE
Arm Type
Placebo Comparator
Arm Description
Oral/enteral placebo matching active Pancreatic Enzymes (PE). Dose presentation in whole sachets of 100mg of granules. For oedematous malnutrition, weight for dosing is reduced by a pragmatic 10%. To be prescribed following enrolment and given just prior to or during a feed. Prescription will follow weight bands: Weight from Weight to Dose Dose Upper range Lower range (Kg) (Kg) (sachets) (IU Lipase) (IU/kg/dose) (IU Lipase) ----------------------------------------------------------------------------------------------------------------------------------------- 2.50 4.99 2 Nil Nil Nil 5.00 7.49 4 Nil Nil Nil 7.50 9.99 6 Nil Nil Nil 10.0 15.0 8 Nil Nil Nil
Arm Title
Ursodeoxycholic acid (UA)
Arm Type
Active Comparator
Arm Description
The dose of ursodeoxycholic acid will be given at 10 mg/kg twice per day just prior to or during a feed, using a suspension of 50 mg/ml = 0.2 ml/kg. For oedematous malnutrition participants, weight is pragmatically reduced by 10%. To be prescribed and given following enrolment.
Arm Title
Placebo-UA
Arm Type
Placebo Comparator
Arm Description
The dose of placebo will be given twice per day just prior to or during a feed at 0.2 ml/kg. To be prescribed and given following enrolment.
Intervention Type
Drug
Intervention Name(s)
Pancreatic Enzyme
Other Intervention Name(s)
CREON
Intervention Description
CREON micro 5000
Intervention Type
Drug
Intervention Name(s)
Ursodeoxycholic acid
Other Intervention Name(s)
UDCAMENT
Intervention Description
Ursodiol C24H40O4 suspension
Intervention Type
Other
Intervention Name(s)
Pancreatic Enzyme placebo
Other Intervention Name(s)
Placebo-PE
Intervention Description
Microcrystalline Cellulose,Macrogel 4000, Iron Oxide Yellow, Iron Oxide Red, Activated Charcoal.
Intervention Type
Other
Intervention Name(s)
Ursodeoxycholic acid placebo
Other Intervention Name(s)
Placebo-UA
Intervention Description
Sodium Citrate Dihydrate, Aspartame, Carboxymethylcellulose Sodium, Citric Acid Monohydrate, Dispersible Cellulose, Glycerol, Polysorbate-80, Saccharin Sodium,Sodium Benzoate, Sodium Methylparaben, Sodium Propylparaben
Primary Outcome Measure Information:
Title
Mortality
Description
Death
Time Frame
60 days
Secondary Outcome Measure Information:
Title
Rate of SAEs
Description
All serious adverse events
Time Frame
60 days
Title
Rate of toxicity events
Description
Grade 3 or 4 toxicity events whilst receiving investigational products
Time Frame
21 days
Title
Intestinal function
Description
number of days with diarrhoea during index hospital admission
Time Frame
60 days
Title
Antimicrobials
Description
Days on second and third-line antibiotics during index admission and readmission
Time Frame
60 days
Title
Hospitalisation duration
Description
Number of days from enrolment to discharge during index admission
Time Frame
60 days
Title
Growth - arm circumference cm
Description
Change in MUAC in cm between enrolment and 60 days later
Time Frame
60 Days
Title
Growth - weight for age z score
Description
Change in weight for age z score between enrolment and 60 days later
Time Frame
60 days
Title
Growth - weight for length z score
Description
Change in weight for length z score between enrolment and 60 days later
Time Frame
60 days
Title
Growth - length for age z score
Description
Change in length for age z score between enrolment and 60 days later
Time Frame
60 days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
2 Months
Maximum Age & Unit of Time
59 Months
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age 2 to <59 months Admitted to hospital with an acute, non-traumatic illness and within 72 hours of admission at the time of enrolment Severe malnutrition (weight-for-height <-3 z scores of the median WHO growth standards and/or mid upper arm circumference <115mm (<110mm age below 6 months), or symmetrical oedema of at least the feet related to malnutrition (not related to a primary cardiac or renal disorder) Able to feed orally in usual state of health. Accompanied by care provider who provides written informed consent Primary caregiver plans to stay in the study area during the duration of the study Presence of two or more features of severity as specified below. If a child meets two criteria, they may be enrolled before further criteria are assessed (e.g. a child may be eligible on clinical signs before the complete blood count results are known): Respiratory distress "Subcostal indrawing" or "nasal flaring" or "head-nodding" Oxygenation "Central cyanosis" or SaO2 <90% Circulation Limb temperature gradient or capillary refill >3 seconds Conscious level AVPU < "A" Pulse > 180 per min Haemoglobin < 7g/dl Blood glucose < 3mmol/L White blood cells < 4 or > 17.5 x 109/L Temperature <36 or >38.5oC Very low MUAC MUAC <11cm Exclusion Criteria:
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
James A Berkley, MD
Organizational Affiliation
University of Oxford
Official's Role
Study Chair
Facility Information:
Facility Name
ICDDR,B Dhaka Hospital
City
Dhaka
Country
Bangladesh
Facility Name
KEMRI WT Clinical Trials Facility
City
Kilifi
ZIP/Postal Code
80800
Country
Kenya
Facility Name
Queen Elizabeth Central Hospital
City
Blantyre
Country
Malawi
Facility Name
Mulago Hospital
City
Kampala
Country
Uganda

12. IPD Sharing Statement

Plan to Share IPD
No
IPD Sharing Plan Description
Anonymised data may be shared through application to DGC@kemri-wellcome.org. Datasets will be uploaded on the HARVARD DATAVERSE for managed access
Citations:
PubMed Identifier
27163928
Citation
Zhang L, Voskuijl W, Mouzaki M, Groen AK, Alexander J, Bourdon C, Wang A, Versloot CJ, Di Giovanni V, Wanders RJ, Bandsma R. Impaired Bile Acid Homeostasis in Children with Severe Acute Malnutrition. PLoS One. 2016 May 10;11(5):e0155143. doi: 10.1371/journal.pone.0155143. eCollection 2016.
Results Reference
background
PubMed Identifier
28912050
Citation
Bartels RH, Bourdon C, Potani I, Mhango B, van den Brink DA, Mponda JS, Muller Kobold AC, Bandsma RH, Boele van Hensbroek M, Voskuijl WP. Pancreatic Enzyme Replacement Therapy in Children with Severe Acute Malnutrition: A Randomized Controlled Trial. J Pediatr. 2017 Nov;190:85-92.e2. doi: 10.1016/j.jpeds.2017.07.013. Epub 2017 Sep 11.
Results Reference
background
PubMed Identifier
30979939
Citation
Njunge JM, Gwela A, Kibinge NK, Ngari M, Nyamako L, Nyatichi E, Thitiri J, Gonzales GB, Bandsma RHJ, Walson JL, Gitau EN, Berkley JA. Biomarkers of post-discharge mortality among children with complicated severe acute malnutrition. Sci Rep. 2019 Apr 12;9(1):5981. doi: 10.1038/s41598-019-42436-y.
Results Reference
background
PubMed Identifier
27655441
Citation
Attia S, Versloot CJ, Voskuijl W, van Vliet SJ, Di Giovanni V, Zhang L, Richardson S, Bourdon C, Netea MG, Berkley JA, van Rheenen PF, Bandsma RH. Mortality in children with complicated severe acute malnutrition is related to intestinal and systemic inflammation: an observational cohort study. Am J Clin Nutr. 2016 Nov;104(5):1441-1449. doi: 10.3945/ajcn.116.130518. Epub 2016 Sep 21.
Results Reference
background
Links:
URL
http://www.chainnetwork.org
Description
The CHAIN Network

Learn more about this trial

Pancreatic Enzymes and Bile Acids in Acutely Ill Severely Malnourished Children

We'll reach out to this number within 24 hrs